US 11,866,491 B2
Antibody for binding to interleukin 4 receptor
Wei Zheng, San Diego, CA (US); Wubin Pan, Richmond (CA); Xin Yang, Taicang (CN); Yang Chen, Taicang (CN); Limin Zhang, Taicang (CN); and Jie Jiang, Taicang (CN)
Assigned to SuZhou Connect Biopharmaceuticals, Inc., Taicang (CN)
Filed by SUZHOU CONNECT BIOPHARMACEUTICALS, LTD., Taicang (CN)
Filed on Aug. 14, 2020, as Appl. No. 16/994,464.
Application 16/994,464 is a division of application No. 16/809,411, filed on Mar. 4, 2020, granted, now 10,774,141.
Application 16/809,411 is a continuation in part of application No. 16/307,930, abandoned, previously published as PCT/CN2017/087592, filed on Jun. 8, 2017.
Claims priority of application No. 201610399254.4 (CN), filed on Jun. 8, 2016.
Prior Publication US 2021/0079088 A1, Mar. 18, 2021
Int. Cl. A61K 39/395 (2006.01); C07K 16/24 (2006.01); A61P 37/08 (2006.01); A61P 29/00 (2006.01); C07K 16/28 (2006.01); C12N 5/12 (2006.01); C12N 15/62 (2006.01); C12N 15/85 (2006.01); A61K 38/00 (2006.01); A61K 45/06 (2006.01)
CPC C07K 16/247 (2013.01) [A61K 39/395 (2013.01); A61P 29/00 (2018.01); A61P 37/08 (2018.01); C07K 16/28 (2013.01); C12N 5/12 (2013.01); C12N 15/62 (2013.01); C12N 15/85 (2013.01); A61K 38/00 (2013.01); A61K 45/06 (2013.01); C12N 2015/8518 (2013.01)] 32 Claims
 
1. A method of treating or ameliorating inflammation or allergic disease in a subject in need thereof, comprising administering to the subject an isolated anti-interleukin 4 receptor (IL-4R) antibody comprising a heavy chain variable domain (VH) comprising three heavy chain complementarity determining regions (CDRs) (CDR-H1, CDR-H2, and CDR-H3), and a light chain variable domain (VL) comprising three light chain CDRs (CDR-L1, CDR-L2, and CDR-L3) wherein:
a. the CDR-L1 comprises the amino acid sequence set forth in SEQ ID NO: 2, the CDR-L2 comprises the amino acid sequence set forth in SEQ ID NO: 3, the CDR-L3 comprises the amino acid sequence set forth in SEQ ID NO: 8, the CDR-H1 comprises the amino acid sequence set forth in SEQ ID NO: 14, the CDR-H2 comprises the amino acid sequence set forth in SEQ ID NO: 18, and the CDR-H3 comprises the amino acid sequence set forth in SEQ ID NO: 19;
b. the CDR-L1 comprises the amino acid sequence set forth in SEQ ID NO: 2, the CDR-L2 comprises the amino acid sequence set forth in SEQ ID NO: 4, the CDR-L3 comprises the amino acid sequence set forth in SEQ ID NO: 8, the CDR-H1 comprises the amino acid sequence set forth in SEQ ID NO: 14, the CDR-H2 comprises the amino acid sequence set forth in SEQ ID NO: 18, and the CDR-H3 comprises the amino acid sequence set forth in SEQ ID NO: 19; or
c. the CDR-L1 comprises the amino acid sequence set forth in SEQ ID NO: 2, the CDR-L2 comprises the amino acid sequence set forth in SEQ ID NO: 4, the CDR-L3 comprises the amino acid sequence set forth in SEQ ID NO: 5, the CDR-H1 comprises the amino acid sequence set forth in SEQ ID NO: 14, the CDR-H2 comprises the amino acid sequence set forth in SEQ ID NO: 18, and the CDR-H3 comprises the amino acid sequence set forth in SEQ ID NO: 19.